fda semaglutide shortage resolved february 21 2025 Ends: Compounded Versions Legal Battle FDA Ends Semaglutide Shortage Listing,

The SUSTAIN 29,30,31,32,33,34,35 and SCALE studies 10,11,12,13,14,15 have shown robust efficacy in lowering blood glucose levels in diabetic patients and inducing weight loss in obese patients over clinical trial periods ranging from 30 to 104 weeks

Eli Lilly, the company that produces tirzepatide, sponsored the study, which was conducted at 32 sites across the United States and Puerto Rico

Semaglutide's potent appetite-suppression effect makes significant weight loss achievable for many patients, which then amplifies lipid improvements beyond what the medication alone would produce

Many people notice they feel satisfied sooner, eat smaller portions, or simply dont think about food as often throughout the day

for other GLP-1 medications, follow specific label guidance